Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 3Other hematologic neoplasm 2Tumor-Agnostic 1Myeloid 1Genitourinary 1Gastrointestinal 1Classical hematology 1Breast 1

Conditions

Myeloproliferative Disorders 1Leukemia, Myeloid, Acute 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Cyclophosphamide 79fludarabine phosphate 75Busulfan 53Whole-Body Irradiation 51Mycophenolic Acid 50Cyclosporine 47Peripheral Blood Stem Cell Transplantation 46fludarabine 42Antilymphocyte Serum 37Melphalan 36Tacrolimus 35Filgrastim 30Cord Blood Stem Cell Transplantation 27Radiotherapy 23Methotrexate 22Cytarabine 22Methylprednisolone 19Granulocyte Colony-Stimulating Factor 18apixaban 17Thiotepa 17Dalteparin 13thymoglobulin 12Rivaroxaban 12Alemtuzumab 12eltrombopag 11ferric carboxymaltose 10Surveys and Questionnaires 10Etoposide 10Epoetin Alfa 10Cyclosporins 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × monalizumab × Classical hematology × Clear all
NCT06892223 2025-03-24

Anti-NKG2A Monoclonal Antibody for AML or MDS Patients Undergoing Haploidentical Transplantation

Istituto Clinico Humanitas

Phase 2 Recruiting
42 enrolled
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Myeloproliferative Disorders, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡